At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Double-blind, Placebo-controlled, Randomized, Single- And Multiple-ascending Dose Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Pf-06293620 In Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 1 clinical trial evaluating PF-06293620 and Placebo for Type 2 Diabetes Mellitus. Completed, enrolled 84 participants across 7 sites.
Detailed Summary
A first in human study to determine the safety, tolerability and pharmacokinetics of single and multiple ascending doses of PF-06293620 in subjects with Type 2 Diabetes Mellitus
Study Details
Timeline
Interventions
subcutaneous, single dose 0.3 mg/kg
Subcutaneous normal saline single dose
Subcutaneous, single dose 1.0 mg/kg
Subcutaneous normal saline single dose
Subcutaneous single dose 3 mg/kg
Subcutaneous normal saline single dose
Subcutaneous single dose 6 mg/kg
Subcutaneous normal saline single dose
Intravenous infusion single dose 1 mg/kg
Intravenous infusion normal saline single dose
Subcutaneous injection multiple dose 75 mg (Days 1, 29 and 57)
Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
Subcutaneous injection multiple dose 150 mg (Days 1, 29 and 57)
Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
Subcutaneous injection multiple dose 250 mg (Days 1, 29 and 57)
Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
Subcutaneous injection multiple dose TBD mg (Days TBD)
Subcutaneous injection normal saline multiple dose (Days TBD)